So far, in clinical studies, [1-11C]acetate PET has been applied for the evaluation of various types of malignant tumor [11]–[14]; hence if the relationship between radiolabeled acetate uptake and FASN-targeted therapy outcome is proved, [1-11C]acetate PET could be promptly applied to predict FASN-targeted therapy outcome. Here, FASN is linked to cancer.